Centre Henri Becquerel

Futó vizsgálatok

• Még nem toboroz

  Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer

  NCT06726330· Forrás

• Még nem toboroz

  FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations

  2026-525763-40-00· 2. fázis· Forrás

• Még nem toboroz

  Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma

  NCT07852377· Forrás

• Toboroz

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· 3. fázis· Forrás

• Még nem toboroz

  Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy

  NCT06439784· Forrás

• Még nem toboroz

  Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

  NCT07463768· 2. fázis· Forrás

• Még nem toboroz

  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

  NCT07624799· 2. fázis· Forrás

• Még nem toboroz

  Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy

  NCT07587814· Forrás

• Még nem toboroz

  SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer

  NCT07241273· Forrás

• Toboroz

  Feasibility Study on the Implementation of a Supervised, Home-based Adapted Physical Activity Program for Patients With Head and Neck Cancer

  NCT07560397· Forrás

• Toboroz

  Cohort of Patients With Chronic Myelomonocytic Leukemia

  NCT07512882· Forrás

• Toboroz

  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT07218341· 4. fázis· Forrás

• Toboroz

  Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

  NCT07043543· Forrás

• Toboroz

  Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

  NCT07371585· 2. fázis· Forrás

• Még nem toboroz

  Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck

  NCT07259915· Forrás

• Toboroz

  Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

  NCT06656598· 2. fázis· Forrás

• Még nem toboroz

  FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.

  2025-521322-14-00· 2. fázis· Forrás

• Toboroz

  Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)

  NCT07190755· Forrás

• Toboroz

  Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

  NCT06559033· Forrás

• Toboroz

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· 3. fázis· Forrás

• Toboroz

  Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

  NCT06918002· 3. fázis· Forrás

• Még nem toboroz

  Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors.

  NCT07029100· Forrás

• Toboroz

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

  NCT06821542· 3. fázis· Forrás

• Toboroz

  Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

  NCT06879704· Forrás

• Toboroz

  Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:

  NCT06817161· 3. fázis· Forrás

• Toboroz

  Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer

  NCT06866938· 2. fázis· Forrás

• Toboroz

  Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

  NCT06625970· 3. fázis· Forrás

• Toboroz

  First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study (OliGRAIL)

  2023-503326-39-00· 3. fázis· Forrás

• Toboroz

  Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA

  NCT06450548· Forrás

• Toboroz

  Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

  NCT06558604· 2. fázis· Forrás

• Toboroz

  A phase II, multicenter, open-label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subjects with untreated or relapsed/refractory high-risk mantle-cell lymphoma

  2023-506706-40-00· 2/3. fázis· Forrás

• Toboroz

  Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

  NCT06450314· 2. fázis· Forrás

• Fut, nem toboroz

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· 3. fázis· Forrás

• Fut, nem toboroz

  Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma

  NCT06744075· Forrás

• Toboroz

  Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone

  NCT06561854· 3. fázis· Forrás

• Toboroz

  RAT-HEMATO : Return to Work After Malignant Hemopathy

  NCT06262789· Forrás

• Toboroz

  Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

  NCT06496581· 3. fázis· Forrás

• Toboroz

  Prospective study in patients with colon or rectum cancer with liver metastasis of the efficacy and toxicity of standard therapy (chemotherapy + targeted therapy) combined with immunotherapy and internal radiotherapy targeting the liver

  NCT04659382· 2. fázis· Forrás

• Toboroz

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· 3. fázis· Forrás

• Toboroz

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· 3. fázis· Forrás

• Toboroz

  Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

  NCT06271057· 2. fázis· Forrás

• Toboroz

  FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY

  2022-501554-11-00· 2. fázis· Forrás

• Toboroz

  An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

  NCT05939414· 3. fázis· Forrás

• Toboroz

  HRD Tests for Ovarian cancER

  NCT06152731· 2. fázis· Forrás

• Toboroz

  Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer

  NCT06027632· Forrás

• Toboroz

  Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

  NCT06022003· 2. fázis· Forrás

• Fut, nem toboroz

  Contribution of Residual Tumour DNA Testing on the Surgical Bed

  NCT05934929· Forrás

• Toboroz

  A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER-81)

  2023-505911-19-00· 2. fázis· Forrás

• Toboroz

  Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

  NCT06191263· 2. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Krónikus limfoid leukémia (CLL)9 toboroz
• Prosztatarák7 toboroz
• Akut mieloid leukémia (AML)6 toboroz
• Áttétes emlőrák6 toboroz
• Fej-nyaki daganatok6 toboroz
• Mielóma multiplex6 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)4 toboroz
• Petefészekrák4 toboroz
• Köpenysejtes limfóma3 toboroz
• Tüdőrák3 toboroz
• Akut limfoid leukémia (ALL)2 toboroz
• Follikuláris limfóma2 toboroz
• Tripla negatív emlőrák2 toboroz
• Glioblasztóma1 toboroz
• Gyermekkori daganatok1 toboroz
• Hólyagrák1 toboroz
• Krónikus mieloid leukémia (CML)1 toboroz
• Máj- és epeúti rák1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Neuroendokrin daganatok1 toboroz
• Pajzsmirigyrák1 toboroz
• Szarkóma1 toboroz
• Vastagbélrák1 toboroz
• Vesedaganat1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer

  NCT07285564· Forrás

• Lezárult

  FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up

  NCT06592846· Forrás

• Lezárult

  A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)

  2023-505910-10-00· 2. fázis· Forrás

• Fut, nem toboroz

  Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  2023-503428-24-00· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· 2. fázis· Forrás

• Lezárult

  Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy

  NCT06141772· Forrás

• Toboroz

  PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

  NCT05581121· 3. fázis· Forrás

• Lezárult

  Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patients with head and neck cancer.

  2022-502584-38-00· 3. fázis· Forrás

• Lezárult

  Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma

  NCT05355987· Forrás

• Lezárult

  Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.

  NCT05303129· Forrás

• Lezárult

  Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

  NCT05008224· 2. fázis· Forrás

• Leállították

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· 1/2. fázis· Forrás

• Lezárult

  ASTX727 AND DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN VERY HIGH RISK MDS OR AML PATIENTS

  NCT04857645· 2. fázis· Forrás

• Lezárult

  BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

  NCT04827719· 2. fázis· Forrás

• Lezárult

  Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

  NCT04703686· 2. fázis· Forrás

• Fut, nem toboroz

  Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

  NCT04404283· 3. fázis· Forrás

• Lezárult

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· 2. fázis· Forrás

• Lezárult

  A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04182204· 3. fázis· Forrás

• Lezárult

  Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Triple-Negative Breast Cancer

  2022-500418-24-00· 2/3. fázis· Forrás

• Lezárult

  Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer

  NCT04008095· Forrás

• Lezárult

  Molecular Profiling of Advanced Soft-tissue Sarcomas

  NCT03784014· 3. fázis· Forrás

• Lezárult

  Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

  NCT03838263· 2. fázis· Forrás

• Lezárult

  Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment

  NCT03832348· Forrás

• Lezárult

  FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

  NCT03723967· 2. fázis· Forrás

• Lezárult

  Phase II Study of Regorafenib as Maintenance Therapy

  NCT03793361· 2. fázis· Forrás

• Lezárult

  Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

  NCT03818061· 2. fázis· Forrás

• Lezárult

  Study of the efficacy of treatment with AG-120 in patients with Myelodysplastic Syndrome and mutation IDH1

  2024-515352-20-00· 2. fázis· Forrás

• Lezárult

  Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

  NCT04069468· Forrás

• Lezárult

  UTOLA: UTerin OLAparib

  NCT03745950· 2. fázis· Forrás

• Lezárult

  Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

  NCT03339843· 2. fázis· Forrás

• Lezárult

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· 3. fázis· Forrás

• Lezárult

  Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients

  NCT03594149· 3. fázis· Forrás

• Lezárult

  A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

  NCT03467373· 1. fázis· Forrás

• Lezárult

  PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .

  NCT03275506· 2. fázis· Forrás

• Lezárult

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· 2. fázis· Forrás

• Lezárult

  Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

  NCT02896582· 2. fázis· Forrás

• Lezárult

  Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

  NCT02924402· 1. fázis· Forrás

• Lezárult

  Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma

  NCT02815137· Forrás

• Lezárult

  Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  NCT02757989· Forrás

• Lezárult

  Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid

  NCT02617745· 2. fázis· Forrás

• Lezárult

  Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC

  NCT02473133· 2. fázis· Forrás

• Lezárult

  French Registry of First-line Treatment of Acute Promyelocytic Leukemia

  NCT02938858· Forrás

• Lezárult

  Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

  NCT02290951· 1. fázis· Forrás

• Lezárult

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· 3. fázis· Forrás

• Lezárult

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· 3. fázis· Forrás

• Lezárult

  Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

  NCT00673335· 3. fázis· Forrás